Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma

Bone Marrow Transplantation

Volumn 46, Issue 6, 2011, Pages 847-851

  Palmer, J ^a   Goggins, T ^b   Broadwater, G ^c   Chao, N ^c   Horwitz, M ^c   Beaven, A ^c   Sullivan, K ^c   Coleman, R E ^c   Rizzieri, D ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Fox Valley Hematology Associates   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

autologous; FDG PET; HSCT; lymphoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY;

ADOLESCENT; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958145027     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.203     Document Type: Article

References (23)

1. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007, pp 571-578.
2. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: A systematic review. J Nucl Med 2008, pp 13-21.
3. Freudenberg LS, Antoch G, Schütt P, Beyer T, Jentzen W, Müller SP et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 325-329. (Pubitemid 38314075)
4. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3989-3994.
5. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59. (Pubitemid 43053523)
6. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-419.
7. Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800. (Pubitemid 34042895)
8. Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 22-28. (Pubitemid 38133537)
9. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in hodgkin's disease and non-hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-433. (Pubitemid 29323856)
10. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37. (Pubitemid 32162445)
11. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514-1523. (Pubitemid 41222425)
12. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102: 53-59. (Pubitemid 36759635)
13. Cremerius U, Fabry U, Wildberger J, Zimny M, Reinartz P, Nowak B et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro- deoxyglucose (FDG) predicts outcome in patients treated with high dose chemotherapy and autologous stem cell transplantation for non-Hodgkins lymphoma. Bone marrow transplantation 2002; 30: 103-111.
14. Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 211-216. (Pubitemid 44102948)
15. Alousi A, Saliba R, Okoroji G-J, Macapinlac HA, Hosing C, Korbling M et al. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 2008; 142: 786-792.
16. Filmont J-E, Gisselbrecht C, Cuenca X, Deville L, Ertault M, Brice P et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007; 110: 1361-1369. (Pubitemid 47435610)
17. Hoppe BS, Moskowitz CH, Zhang Z, Maragulia JC, Rice RD, Reiner AS et al. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant 2009; 43: 941-948.
18. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-1996. (Pubitemid 37122371)
19. Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff GW, Pruim J, Vaalburg W et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007, pp 486-491.
20. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623. (Pubitemid 32113392)
21. Harrell Jr FE. Regression Modelling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis, 1st edn. Springer: New York, NY, USA, 2001.
22. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J et al. New prognostic score based on treatment outcome of patients with relapsed hodgkin's lymphoma registered in the database of the german hodgkin's lymphoma study group. J Clin Oncol 2002; 20: 221-230. (Pubitemid 34032615)
23. Moskowitz CH, Schoder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010; 28: 1896.